Angel Biotechnology and Novolytics sign manufacturing agreement

Under the contract, Angel will manufacture and supply GMP materials for use in a bacteriophage-based MRSA prophylactic treatment as part of a Phase I/II clinical trial scheduled to commence in 2009.

The GMP production project will be carried out over a period of seven months at Angel’s facilities in Edinburgh.

Gordon Sherriff, Angel’s COO, said: “This is a significant project for Angel. The specialist nature of the work draws on Angel’s core expertise in finding GMP solutions for such projects. The project fits well with Angel’s strategic direction and will further enhance our reputation in this new and exciting field.”